TherMatrx® Office Thermo Therapy™ is an advanced transurethral microwave thermotherapy system designed for in-office treatment of mild to moderate symptoms of benign prostatic hyperplasia (BPH). Proven safe and effective, minimally invasive and clinically efficacious, TherMatrx requires only mild oral medications. ¹

TherMatrx is a widely used in-office BPH thermotherapy treatment in the United States. Unlike surgical solutions for BPH, TherMatrx does not require cutting, heavy sedation or hospitalization. A single TherMatrx treatment administered in your office can provide lasting symptom relief.

What makes TherMatrx unique is the "dose optimization" that it brings to thermotherapy, delivering the optimal dose of heat needed for each patient to provide significant relief of BPH symptoms with minimal side effects and excellent in-office tolerance.

1. Transurethral Microwave Thermotherapy System. TherMatrx TMx-2000™. PMA P000043 summary of safety and effectiveness data. Approved June 29, 2001. Available at: www.fda.gov/cdrh/pdf/p000043.html.

TherMatrx System Description

The patented TMX3000 System is a computer controlled thermo therapy treatment device that delivers microwave energy to the prostate. The system computer monitors all treatment parameters and automatically adjusts the microwave energy as needed to achieve and maintain thermo therapeutic temperatures for the selected duration of treatment.

Disposables

Treatment catheter - 4 different lengths

Features & Benefits

Single in-office treatment

• Easily integrated into your office with minimal patient prep and recovery time
• Does not require use of monitoring equipment such as EKG or crash cart
• Non-surgical treatment performed in the comfort and convenience of your office ¹

Exceptional Ease of Use

• Three protocol options ranging in treatment time from 38 - 62 minutes
• Touch-screen monitor provides increased ease of use
• Autocalibration of temperature sensors

Proven Safe and Effective

• 5-year clinical data supports sustained quality of life with an exception safety profile ²
• Post-treatment side effects like bladder spasms or hematuria were generally transitory, minor and self-resolving ¹
• Less than 1% reported cases of erectile dysfunction ¹
• 47.1% improvement in AUA symptom score and 58.1% improvement in Peak Flow Rate ¹
• UL certified

Exception Patient Tolerance

• Only mild oral medications are needed for excellent patient tolerance and comfort during treatment

1 TherMatrx-2000 BPH Thermotherapy System. P000043. FDA Approved 6-29-01. Summary available at www.fda.gov/cdrh/pdf/P000043.html.

2 Data on file at AMS.